News

Gralise tablet is developed by Depomed and is licensed to Abbott Products in US, Mexico and Canada. The FDA has approved Gralise tablets as once daily treatment of

The preclinical programmes of AFFiRiS’ two vaccine candidates, generated by its AFFITOME technology, have been completed successfully. Meanwhile, its lead vaccine candidate AD02 is currently in phase II

Health Robotics claims that CytoCare guarantees a dosage accuracy within 95%+. The therapeutic window of medications can be optimally used, providing your patients with the most effective treatment.

Two classes of bowel cancer cells grown in the lab were treated with around 250 compounds including common chemotherapy drugs used in bowel cancer and newer ‘targeted’ drugs

Rilonacept, also known as IL-1 Trap, is an agent that inhibits IL-1 (interleukin 1) and is indicated in the US for the treatment of Cryopyrin-associated periodic syndromes (CAPS),

The trial aimed at blocking the virus so that patients do not need antiviral drugs, and was designed to evaluate the safety and clinical outcomes of Sangamo’s zinc

Bayer had recorded a profit of $211m in the same period of 2009, and analysts had forecast a 2010 fourth quarter profit of $219m, which did not come

Daiichi will be paying $805m up-front with near-term milestone payments associated with the approval of Plexxikon’s melanoma treatment drug PLX4032 adding up to another $130m. The acquisition will

Infusion pumps are medical devices that deliver fluids, including nutrients and medications such as antibiotics, chemotherapy drugs, and pain relievers, into a patient’s body in controlled amounts and